DSIP (Delta Sleep-Inducing Peptide)

What is DSIP?

DSIP is a short peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) studied for its link to sleep regulation. Researchers Marcel Monnier and Guido Schoenenberger isolated the substance from the cerebral venous blood of rabbits that had been driven into a sleep like state by low frequency electrical stimulation of the thalamus (Schoenenberger and Monnier, 1977). When they characterized the fraction responsible for the delta EEG pattern, they identified a peptide and gave it the descriptive name delta sleep-inducing peptide.

That origin matters for how you read every later claim. DSIP was defined by an EEG signature in an animal model, not by a modern clinical endpoint. The peptide is endogenous, meaning the body makes it, and it has been detected in both brain tissue and peripheral blood, which is part of why its exact physiological role is still debated.

How does DSIP work?

The short answer: the mechanism is not fully mapped, and the original naming came from an observed EEG effect rather than a confirmed receptor pathway. In the founding work, infusion of the isolated peptide increased delta (slow wave) EEG activity in recipient animals (Schoenenberger and Monnier, 1977). Later research explored roles in circadian signaling, stress response, and neuromodulation, but no single receptor has been established as the definitive DSIP target in the way GLP-1 receptor agonists have a defined receptor.

Because of this, DSIP is best described as a neuromodulatory peptide with sleep associated effects reported in early literature, rather than a compound with a settled mechanism of action. Treat any confident mechanistic story with skepticism.

What does the research actually report?

Direct answer: the strongest historical signal is an increase in delta EEG activity in animal models, while human results are older, smaller, and inconsistent.

This is the honest state of the field. Where newer compounds carry large registration trials, for example semaglutide in STEP 1 with about 15 percent mean weight loss (Wilding et al., 2021), DSIP has no comparable modern evidence base. That gap is the reason to be cautious about strong marketing claims.

What dose did research use, and what is the half-life?

Direct answer: published human dose-response data are limited, so no standard research dose is well established, and this page does not tell you what to take.

DSIP's early characterization used intraventricular and systemic infusion in animals rather than the fixed human dosing schedules seen with modern peptides (Schoenenberger and Monnier, 1977). Human studies from later decades used varied routes and amounts, but the small sample sizes and mixed endpoints mean these numbers do not add up to a validated protocol. Because rule number one of reading this compound is that the data are thin, we will not present a precise human milligram schedule as if it were settled science.

On stability: reported plasma persistence of DSIP is short, on the order of minutes, which is common for small peptides, though human pharmacokinetic data remain sparse and should not be over-read. Any decision about form, amount, or timing belongs with a qualified clinician who can weigh your history.

Is DSIP safe? What are the reported side effects?

Direct answer: the safety profile is not well characterized in modern controlled trials, which is itself the main caution.

Early studies did not flag a dramatic acute toxicity signal in the small groups examined, but absence of large modern safety data is not the same as proven safety. Compare this with peptides that do have documented side effect rates, such as bremelanotide (PT-141), where nausea was reported in about 40 percent of participants in its phase 3 program (RECONNECT, 2019), or MK-677, which raised fasting glucose and lowered insulin sensitivity in older adults (Nass et al., 2008). DSIP lacks that level of characterized adverse event reporting, so unknowns dominate. This is a research compound, and the responsible framing is uncertainty, not reassurance.

How does DSIP compare to other calming or recovery peptides?

Direct answer: DSIP is a sleep associated neuropeptide with a thin modern evidence base, while its common "neighbors" are studied for calm and recovery through different routes.

Readers often group DSIP with Selank, a peptide discussed in the calm and anti-anxiety space, and with broader recovery focused compounds. These are separate molecules with separate literatures. The shared theme is that human controlled data for most of this category are limited, so cross-compound comparisons should stay descriptive rather than promotional. See the recovery hub and the Selank page linked below for those specific profiles.